Oracle shares surge 3.34% as rebuttal to OpenAI delay report and healthcare contracts boost confidence

Tuesday, Dec 23, 2025 8:02 am ET1min read
Aime RobotAime Summary

-

shares rose 3.34% pre-market after refuting Bloomberg's OpenAI delay claims and securing contracts.

- Analysts argue market volatility overestimated risks, though

cut price target to $220 amid AI spending concerns.

- Upcoming OpenAI timelines and capex guidance will shape investor sentiment in the competitive cloud-AI sector.

Oracle shares surged 3.34% in pre-market trading on December 23, 2025, driven by renewed investor confidence in its AI infrastructure positioning.

The upward momentum followed Oracle's rebuttal of a Bloomberg report suggesting OpenAI's data-center work would delay to 2028, easing fears over execution risks for a key revenue catalyst. Concurrently, new healthcare contracts—including Mt. San Rafael Hospital adopting

Health—provided tangible near-term visibility, reinforcing growth in cloud software services.

Analysts highlighted that recent market volatility had overstated Oracle's fundamentals, prompting a "buy the dip" narrative. However, Goldman Sachs' sharp price target cut to $220 from $320 underscored lingering concerns about AI capital expenditures and debt management. Broader industry-wide selloffs in AI infrastructure stocks also weighed on sentiment, though Oracle's customer wins and strategic clarity helped offset some of the pressure.

Investors remain focused on upcoming disclosures regarding OpenAI timelines, capex guidance, and potential analyst revisions to gauge the next phase of Oracle's trajectory in the competitive cloud-AI landscape.

Comments



Add a public comment...
No comments

No comments yet